Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by EternalPonzion Feb 05, 2020 2:03pm

106 Views

Post# 30647187

RE:RE:RE:RE:Whoever has listened to Francine

DITTO! The market is fickle and if you haven't figured it out by now, a huge Ponzi scheme, kept afloat by Central Bank/Government desperation. Damage is done to stocks all the time for a plethora of reasons. As quickly as damage is done, it can just as easily be undone. Mind you, a 'momentum' price as been paid which is difficult to quantify.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute